This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
AHEAD was a randomized, double-masked, parallel phase 3 treatment trial in asthma with an enrollment of 2100 participants. The registered primary endpoint was time to first severe asthma exacerbation.
| Feature | AHEAD |
|---|---|
| Trial acronym | AHEAD |
| ClinicalTrials.gov identifier | NCT00242775 |
| Phase | Phase 3 |
| Condition | Asthma |
| Enrollment | 2100 |
| Allocation | Randomized |
| Design model | Parallel |
| Masking | Double |
| Primary purpose | Treatment |
| Status | Completed |
| Start date | 2005-05 |
| Lead sponsor | AstraZeneca |
| Sponsor type | Industry |
| Primary endpoint | Time to first severe asthma exacerbation |
2. Clinical Question
The central statistical question is whether the randomized treatment comparison produces a difference in the time to first severe asthma exacerbation among participants with asthma.
Population
Participants with asthma enrolled in the phase 3 AHEAD trial.
Intervention
Budesonide/formoterol Turbuhaler.
Comparator
The registered trial title identifies salmeterol/fluticasone Diskus 50/500 µg and terbutaline Turbuhaler 0.4 mg as comparators/interventions in the study.
Primary question
How does treatment assignment relate to the time until the first severe asthma exacerbation?
3. Trial Design
Registered interventions
Budesonide/formoterol Turbuhaler
- Registered as a drug intervention.
- Included in the registered AHEAD trial title.
Salmeterol/fluticasone Diskus 50/500 µg
- Registered as a drug intervention.
- Included in the registered AHEAD trial title.
4. Endpoints
| Endpoint | Registry definition | Statistical character |
|---|---|---|
| Primary endpoint | Time to first severe asthma exacerbation | Time-to-event endpoint |
The endpoint is inherently different from a simple binary outcome such as whether a participant ever experienced an exacerbation. A time-to-event analysis uses both whether the event occurred and the amount of observed event-free time.
Participants who have not experienced the first event by the end of their observed follow-up can contribute censored information rather than being treated as if the event never could occur.
5. Results Status
The ClinicalTrials.gov record identifies the trial as COMPLETED, but no formal statistical analyses are posted in the registry information available here.
Accordingly, the appropriate statistical focus is the prespecified endpoint and the methods that would normally be used to analyze it rather than an outcome estimate.
6. Planned Analysis
The primary endpoint is a time-to-first-event outcome. For a randomized parallel-group trial of this type, the statistical analysis would normally compare the time-to-event distributions between randomized treatment groups while appropriately handling participants whose first severe asthma exacerbation has not occurred by the end of observation.
Kaplan-Meier estimation
A Kaplan-Meier estimator can describe the probability of remaining free of the first severe asthma exacerbation over time. It accommodates right censoring by allowing participants to contribute information up to their last observed event-free time.
di is the number of first events at time ti, and ni is the number of participants at risk immediately before that time.
Log-rank comparison
A log-rank test is commonly used to compare two or more time-to-event distributions under the null hypothesis that the groups have the same event-time distribution. In a randomized study, the comparison is anchored to treatment assignment rather than to post-randomization characteristics.
Cox proportional-hazards model
A Cox proportional-hazards model is commonly used to estimate a hazard ratio for the treatment comparison. The hazard ratio summarizes the relative instantaneous event rate between groups over the analyzed follow-up under the proportional-hazards framework.
A hazard ratio is not an absolute risk difference, does not directly state how many participants avoid an exacerbation, and does not equal the ratio of median times unless very restrictive assumptions hold.
7. Statistical Methodology
Time-to-event analysis
The defining feature of the primary endpoint is that time matters. Two participants who both experience a severe asthma exacerbation do not necessarily provide equivalent information if one experiences the event shortly after randomization and another remains event-free for substantially longer.
Likewise, a participant who has not experienced the event by the end of follow-up should not automatically be coded as an event-free participant for all future time. Instead, that participant contributes information through the period during which the event status is known. This is the role of censoring in survival analysis.
Hazard versus probability
The hazard is an instantaneous event rate conditional on remaining event-free immediately before a given time. It should not be interpreted as the probability that an individual participant will experience an exacerbation during the entire study.
This distinction is important because a hazard ratio and a cumulative event probability answer different questions. A treatment comparison can have a hazard ratio below 1 while the absolute difference in event-free probability varies over time.
Randomization
Randomization provides the foundation for a causal comparison between treatment assignments. In expectation, randomization balances both measured and unmeasured baseline characteristics across groups. It therefore permits differences observed after randomization to be interpreted within the randomized comparison, subject to the usual assumptions and limitations of clinical-trial inference.
Double masking
Double masking is particularly relevant when outcomes or behavior could be influenced by knowledge of treatment assignment. Masking can reduce such risks by limiting awareness of treatment allocation among participants and study personnel, although the precise identities of the masked parties are not specified in the registry information available here.
8. Statistical Methods Explained
Why is the primary endpoint analyzed as a time-to-event outcome?
“Time to first severe asthma exacerbation” contains more information than a yes/no endpoint. A participant who remains event-free for a long period contributes information about the treatment comparison even if the participant never experiences the event during observed follow-up. Time-to-event methods are designed to use this information while accounting for censoring.
What does a Kaplan-Meier curve represent?
A Kaplan-Meier curve estimates the probability of remaining free of the first severe asthma exacerbation as time progresses. Each observed first event changes the estimated event-free survival, while censoring reduces the number considered at risk after the censoring time without being treated as an event.
Why would a log-rank test be appropriate?
The log-rank test provides a comparison of the observed event timing between randomized groups across follow-up. It is designed for time-to-event data and is therefore more informative for this endpoint than a simple comparison of the proportion of participants who eventually experienced an exacerbation.
What would a hazard ratio mean in this trial?
A hazard ratio would describe the relative instantaneous rate of first severe asthma exacerbation between treatment groups under the Cox model. A value below 1 would indicate a lower estimated hazard in the treatment group, whereas a value above 1 would indicate a higher estimated hazard. It would not directly represent an individual's probability of avoiding an exacerbation.
Why does censoring matter?
Not every participant will necessarily be observed until the first severe asthma exacerbation. Participants can reach the end of available follow-up without an event. Time-to-event methods incorporate their known event-free observation period rather than treating them as having unlimited event-free survival.
Why is proportional hazards an important assumption?
A Cox hazard ratio has a particularly straightforward interpretation when the relative hazards are reasonably stable over time. If the treatment effect changes substantially over follow-up, a single hazard ratio may compress a more complicated time-varying pattern into one summary measure. Examination of the underlying survival curves and other time-specific measures can therefore be important.
9. Primary Endpoint Interpretation Framework
A hazard ratio would summarize the relative instantaneous rate of the first severe asthma exacerbation between the randomized treatment groups. It would provide a relative measure of treatment effect over the analyzed follow-up.
A hazard ratio would not by itself provide the absolute probability of a severe asthma exacerbation at a particular time, the number needed to treat, or the proportion of participants who personally benefited.
A confidence interval around a treatment-effect estimate would describe statistical uncertainty under the specified model and sampling framework. A narrow interval would indicate greater precision than a wide interval, all else being equal.
A p-value addresses evidence against a specified null hypothesis under the statistical model. It does not describe the magnitude of a treatment effect. Effect estimates and their confidence intervals are needed to understand magnitude and precision.
10. Analysis Population Considerations
The registry information available here establishes that AHEAD was randomized, but it does not specify the exact analysis populations used for efficacy or safety, nor does it identify whether analyses were conducted according to an intention-to-treat principle, a per-protocol population, an as-treated population, or another defined set.
| Question | What the registry information establishes |
|---|---|
| Was the trial randomized? | Yes. |
| Was the design parallel? | Yes. |
| Was the study double-masked? | Yes. |
| Was the exact efficacy analysis population reported? | Not in the information available here. |
| Was the exact censoring rule reported? | Not in the information available here. |
| Was a specific Cox model reported? | Not in the information available here. |
| Were formal statistical results posted? | No posted statistical analyses are identified. |
11. Multiplicity and Multiple Treatment Comparisons
The registered trial title identifies three treatment products: budesonide/formoterol Turbuhaler, salmeterol/fluticasone Diskus 50/500 µg, and terbutaline Turbuhaler 0.4 mg. A multi-treatment study can generate multiple pairwise treatment comparisons.
When more than one confirmatory comparison is performed, the overall probability of a false-positive conclusion can exceed the nominal significance level unless the statistical design accounts for multiplicity. Appropriate methods can include hierarchical testing, adjusted significance levels, closed testing procedures, or other prespecified approaches.
12. Censoring and Missing Data
Because the primary endpoint is a time-to-first-event outcome, censoring is an intrinsic component of the analysis. The validity of a time-to-event comparison depends on how censoring occurs and how the analysis accounts for it.
The registry information available here does not specify the detailed censoring rules, reasons for censoring, handling of treatment discontinuation, or missing-data and imputation procedures.
Event observed
The participant contributes an observed time to the first severe asthma exacerbation.
Event not observed during follow-up
The participant can contribute a censored event-free observation through the last known follow-up time.
13. Interim Analysis and Sequential Monitoring
The available registry information does not report an interim analysis plan, stopping boundaries, alpha-spending approach, information fractions, or a group-sequential monitoring strategy for AHEAD.
These features matter when accumulating trial data are examined before the final analysis because repeated unadjusted testing can alter the overall type I error. A valid sequential design specifies in advance how evidence will be evaluated over time.
14. Safety Analysis Considerations
The ClinicalTrials.gov information available here identifies the trial as a treatment study and provides the registered intervention information, but it does not provide arm-specific serious adverse-event counts or other safety results.
Safety analysis in a randomized treatment trial is conceptually distinct from the time-to-first-severe-asthma-exacerbation efficacy endpoint. Efficacy addresses the prespecified clinical outcome, whereas safety summarizes adverse events and other harms associated with treatment exposure.
| Safety information | Registry information available here |
|---|---|
| Serious adverse events by arm | Not reported. |
| Overall adverse-event rates by arm | Not reported. |
| Specific adverse-event counts | Not reported. |
| Formal safety analysis method | Not reported. |
15. Why This Trial Matters Statistically
AHEAD is a useful statistical teaching case because its registered primary endpoint is a classic time-to-first-event outcome embedded in a randomized, double-masked, parallel phase 3 treatment design.
| Concept | How it appears in AHEAD |
|---|---|
| Randomization | The trial uses randomized allocation to compare treatment strategies. |
| Parallel design | The registry classifies the design model as parallel. |
| Double masking | The registry classifies the study as double-masked. |
| Time-to-event analysis | The primary endpoint is time to first severe asthma exacerbation. |
| Kaplan-Meier estimation | A standard method for describing time to first event while accounting for censoring. |
| Log-rank testing | A standard framework for comparing time-to-event distributions between randomized groups. |
| Cox regression | A standard model for estimating a hazard ratio for a time-to-event treatment comparison. |
| Censoring | Participants without an observed first event during follow-up can contribute censored event-free time. |
| Multiplicity | Multiple registered treatment products can create multiple potential comparisons that require prespecified statistical control if treated as confirmatory tests. |
16. Limitations
- No posted statistical results: the ClinicalTrials.gov record available here does not provide formal statistical analyses or numerical efficacy estimates for the primary endpoint.
- Limited endpoint detail: the registry identifies time to first severe asthma exacerbation but does not provide a more detailed operational definition or assessment time frame in the information available here.
- Unspecified analysis model: the registry information does not identify the exact statistical model used for the primary endpoint.
- Unspecified analysis population: the registry information does not define the exact population used for the primary efficacy analysis.
- Unspecified censoring rules: the registry information does not describe how censoring was defined or handled.
- Unspecified multiplicity strategy: the registry information does not state how multiple treatment comparisons, if formally tested, were controlled.
- No safety estimates: arm-specific serious adverse-event results and other numerical safety outcomes are not provided in the available registry information.
- Incomplete intervention detail: the registered trial title identifies three treatment products, while the structured intervention field identifies two drug interventions; the available record does not provide a complete arm-by-arm allocation table.
17. What the Primary Endpoint Can and Cannot Establish
What it can establish
A properly analyzed randomized comparison can estimate whether the time distribution for the first severe asthma exacerbation differs between treatment assignments.
What it cannot establish alone
The endpoint alone does not summarize every aspect of treatment benefit, safety, long-term disease control, or individual patient experience.
This distinction is important when interpreting a clinical trial with a single primary endpoint. A statistically detectable difference in time to first exacerbation is one component of the evidence, while treatment safety and other clinically relevant outcomes require separate evaluation.
18. Clinical Interpretation vs Statistical Interpretation
Statistical interpretation
The registered primary outcome is a time-to-event endpoint. Its analysis would ordinarily use methods that account for event timing and censoring, with treatment assignment as the randomized comparison.
Clinical interpretation
The clinical question concerns whether participants remain free of a severe asthma exacerbation for different lengths of time under the randomized treatment strategies. The registry information available here does not provide an outcome estimate with which to quantify that difference.
19. Sources and Registry Information
- ClinicalTrials.gov record: AHEAD (NCT00242775).
- PubMed record: PubMed record 22932169.
- PubMed record: PubMed record 17905575.
Explore Clinical Trial Statistics
Continue with Clinical Biostats resources on clinical-trial design, survival analysis, and statistical methodology.